Wells Fargo analyst Larry Biegelsen has maintained their bullish stance on MMSI stock, giving a Buy rating today.
Larry Biegelsen has given his Buy rating due to a combination of factors that highlight Merit Medical Systems’ strong performance and growth potential. The company’s Q4 results showed a significant revenue increase, with a 10.1% rise excluding foreign exchange impacts and a 6.1% organic growth year-over-year, aligning with prior forecasts. Notably, the OEM segment outperformed expectations, contributing to the positive outlook.
Moreover, Merit Medical Systems provided 2025 sales guidance that exceeded consensus estimates, indicating robust future growth, particularly in the Cardiovascular and Endoscopy segments. Although the EPS guidance for 2025 was below consensus due to higher interest expenses and dilution from convertible debt, the underlying EPS growth excluding these factors was projected at 9-12% year-over-year. This underlying strength, coupled with anticipated revenue growth, supports the Buy rating despite the challenges posed by accounting adjustments.
According to TipRanks, Biegelsen is a 5-star analyst with an average return of 13.1% and a 63.60% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Dexcom, and Intuitive Surgical.
In another report released today, Needham also maintained a Buy rating on the stock with a $116.00 price target.